TENX

Business Context and Reporting Period

Company: Synthetic Blood International, Inc. (SBI)
Filing Type: Form 10-K
Period Ended: April 30, 2003
Status: Development-stage enterprise with no commercial revenue.
Core Business: SBI is developing three primary medical products based on perfluorocarbon (PFC) and biosensor technology: Oxycyte (a synthetic blood substitute), Fluorovent (a liquid for oxygen exchange in respiratory distress), and an implantable continuous glucose biosensor for diabetics. The company relies on third-party partnerships for future commercialization and manufacturing.

Key Financial Metrics

Notes: The company has no long-term debt as of April 30, 2003. Total assets decreased significantly from $3.28 million in 2002 to $914,905 in 2003.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately 36% to $2.23 million in 2003 compared to $3.49 million in 2002. This improvement was primarily driven by a $1.55 million non-cash expense in 2002 related to the issuance of stock warrants, which did not recur in 2003.
• Expense Management: General and Administrative (G&A) expenses dropped 63% to $840,352, excluding the one-time warrant expense from the prior year. Research and Development (R&D) expenses increased 9% to $1.43 million, reflecting increased spending on Oxycyte as it approached Phase I clinical trials.
• Liquidity Decline: Cash and cash equivalents plummeted by 93% to $178,442. Working capital decreased from $2.35 million to $236,869. The company used $2.09 million in cash for operations during the fiscal year.
• Debt Repayment: The company repaid all short-term notes payable ($105,569) during the fiscal year, resulting in zero notes payable on the balance sheet.

Outlook, Risks, and Management Commentary

Going Concern Warning: The independent auditors have issued a "substantial doubt" opinion regarding the company's ability to continue as a going concern. The company has an accumulated deficit of $18.7 million and requires substantial additional financing to fund operations and clinical trials.

Capital Resources: Management believes existing cash plus $900,000 in deposits received subsequent to April 30, 2003 (part of an anticipated $2 million stock placement), will fund operations for approximately one year. No other financing commitments are currently in place.

Product Pipeline:

• Oxycyte: IND approved by the FDA; Phase I clinical trials expected in the second half of calendar 2003.
• Fluorovent and Glucose Biosensor: Remain in preclinical stages.

Risk Factors:

• Financing Risk: Failure to secure additional capital could force the company to curtail or cease operations.
• Regulatory Risk: No assurance that FDA approval will be granted for any product candidates.
• Commercialization Risk: The company has no sales infrastructure and intends to rely on third-party partners for marketing and manufacturing.
• Competition: Intense competition from companies with greater financial resources and advanced clinical trial stages.

Investor Verification Checklist

• Capital Sufficiency: Verify the status of the anticipated $2 million common stock placement and whether the full amount has been secured to fund the projected 12-month runway.
• Clinical Trial Timeline: Confirm the start date and progress of the Phase I clinical trials for Oxycyte, as delays could accelerate cash burn.
• Partnership Agreements: Investigate if any definitive partnership agreements have been signed with pharmaceutical or medical device companies to share development costs, as the company currently has none.
• Stock Dilution: Review the terms of the new stock placement and the 8.5 million warrants issued to the placement agent, which will significantly dilute existing shareholders.
• Going Concern Status: Monitor subsequent filings for any further auditor qualifications or indications of liquidity crises.